Otoacoustic Emissions in Different Blood Types

The Association of Blood Type Differences and Signal-Noise Ratio in TEOAE and DPAOE in Individuals With Normal Hearing

The objective of this study is to examine whether ABO and Rhesus (Rh) blood group systems have an association with distortion product otoacoustic emission (DPOAE) and transient otoacoustic emission (TEOAE) amplitudes with the hypothesis of blood groups may affect hearing thresholds.

Study Overview

• Status: Completed
• Conditions: Hearing Loss, Cochlear
• Intervention / Treatment: Diagnostic test: Otoacoustic emissions (non-invasive)

Detailed Description

Many factors have a significant impact on otoacoustic emission (OAE) measurement and quality of analysis. Race, age and gender are among the non-pathological factors. To date there is clear data to demonstrate the association of blood types with OAEs. The aim of our research is to investigate the relation of different blood groups (ABO) and Rh factors on transient evoked OAE and distortion product OAE amplitudes and inner ear potentials, differences between ears and to contribute to the limited literature on cochlear hearing loss susceptibility and blood groups with the hypothesis that blood groups may be associated with hearing thresholds.

• Study Type: Observational
• Enrollment (Actual): 70

Contacts and Locations

Study Locations

• Turkey
  • İstanbul, Turkey, 34107
    • Eyyup KARA

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Individuals between the ages of 18-26 with known blood type without hearing loss

Description

Inclusion Criteria:

• not having hearing loss
• having a blood group card obtained from health institutions

Exclusion Criteria:

• not meeting inclusion criteria

Study Plan

How is the study designed?

Number of groups / cohorts

8

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Individuals with A Rh (+) blood group; Individuals with normal hearing and whose blood group was previously determined as A Rh (+) will be included and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.	Diagnostic test: Otoacoustic emissions (non-invasive); There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Individuals with A Rh (-) blood group; Individuals with normal hearing and whose blood group was previously determined as A Rh (-) will be included and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.	Diagnostic test: Otoacoustic emissions (non-invasive); There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Individuals with B Rh (+) blood group; Individuals with normal hearing and whose blood group was previously determined as B Rh (+) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.	Diagnostic test: Otoacoustic emissions (non-invasive); There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Individuals with B Rh (-) blood group; Individuals with normal hearing and whose blood group was previously determined as B Rh (-) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.	Diagnostic test: Otoacoustic emissions (non-invasive); There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Individuals with AB Rh (+) blood group; Individuals with normal hearing and whose blood group was previously determined as AB Rh (+) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.	Diagnostic test: Otoacoustic emissions (non-invasive); There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Individuals with AB Rh (-) blood group; Individuals with normal hearing and whose blood group was previously determined as AB Rh (-) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.	Diagnostic test: Otoacoustic emissions (non-invasive); There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Individuals with O Rh (+) blood group; Individuals with normal hearing and whose blood group was previously determined as O Rh (+) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.	Diagnostic test: Otoacoustic emissions (non-invasive); There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Individuals with O Rh (-) blood group; Individuals with normal hearing and whose blood group was previously determined as O Rh (-) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.	Diagnostic test: Otoacoustic emissions (non-invasive); There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Signal to noise ratios	SNRs obtained for different frequencies in OAE In TEOAE, 1, 1.4, 2, 2.8, 4 kHz, in DPOAE 1, 1.4, 2, 2.8, 4, 6 kHz	1 month

Collaborators and Investigators

• Sponsor: Istanbul University - Cerrahpasa (IUC)
• Investigators: Principal Investigator: Eyyup Kara, PhD, Istanbul University - Cerrahpasa (IUC)

Study record dates

Study Major Dates

• Study Start (Actual): February 7, 2024
• Primary Completion (Actual): March 12, 2024
• Study Completion (Actual): March 18, 2024

Study Registration Dates

• First Submitted: March 18, 2024
• First Submitted That Met QC Criteria: March 18, 2024
• First Posted (Actual): March 22, 2024

Study Record Updates

• Last Update Posted (Actual): March 26, 2024
• Last Update Submitted That Met QC Criteria: March 23, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: otoacoustic emissions; blood type
• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Otorhinolaryngologic Diseases; Ear Diseases; Sensation Disorders; Hearing Disorders; Hearing Loss; Hearing Loss, Sensorineural
• Other Study ID Numbers: E-74555795-050.04-941208

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: No data sharing is planned.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No